NEW YORK, Aug. 1, 2013 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of TearLab Corporation ("TearLab" or the "Company") (NasdaqCM: TEAR -News). The investigation focuses on whether the Company and its executives violated federal securities laws.
On August 1, 2013, an article appeared on The Street Sweeper alleging that some of the doctors listed on the Company's website were providers of its diagnostic test for dry eye disease ("DED") no longer use the machine and had already returned it. On this news, shares of TearLab fell $1.30 or 9.19% to close at $12.85.
If you are aware of any facts relating to this investigation, or purchased shares of TearLab you can assist this investigation by contacting either Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC